Works by Wang, Judy S.

Results: 16

TRUCK TECHNOLOGY AND EFFICIENT MARKET STRUCTURE.

Published in:

Review of Economics & Statistics, 1985, v. 67, n. 2, p. 250, doi. 10.2307/1924724

By:

Chiang, Judy S. Wang;
Friedlaender, Ann F.

Publication type:

Article

OUTPUT AGGREGATION, NETWORK EFFECTS, AND THE MEASUREMENTS OF TRUCKING TECHNOLOGY.

Published in:

Review of Economics & Statistics, 1984, v. 66, n. 2, p. 267, doi. 10.2307/1925827

By:

Chiang, S. Judy Wang;
Friedlaender, Ann F.

Publication type:

Article

A Practical Pact for the Pure Land.

Published in:

JAMA: Journal of the American Medical Association, 2008, v. 299, n. 12, p. 1405, doi. 10.1001/jama.299.12.1405

By:

Wang, Judy S.

Publication type:

Article

Safety, tolerability, and pharmacokinetics of Aurora kinase B inhibitor AZD2811: a phase 1 dose-finding study in patients with advanced solid tumours.

Published in:

British Journal of Cancer, 2023, v. 128, n. 10, p. 1906, doi. 10.1038/s41416-023-02185-2

By:

Johnson, Melissa L.;
Wang, Judy S.;
Falchook, Gerald;
Greenlees, Carol;
Jones, Suzanne;
Strickland, Donald;
Fabbri, Giulia;
Kennedy, Caroline;
Elizabeth Pease, J.;
Sainsbury, Liz;
MacDonald, Alexander;
Schalkwijk, Stein;
Szekeres, Philip;
Cosaert, Jan;
Burris III, Howard

Publication type:

Article

Effects of sildenafil and/or muscle derived stem cells on myocardial infarction.

Published in:

Journal of Translational Medicine, 2012, v. 10, n. 1, p. 159, doi. 10.1186/1479-5876-10-159

By:

Wang, Judy S. C.;
Kovanecz, Istvan;
Vernet, Dolores;
Nolazco, Gaby;
Kopchok, George E.;
Chow, Sheryl L.;
White, Rodney A.;
Gonzalez-Cadavid, Nestor F.

Publication type:

Article

Phase I, first-in-human trial of programmed cell death receptor-1 (PD-1) inhibitor, JTX-4014, in adult patients with advanced, refractory, solid tumors.

Published in:

Cancer Immunology, Immunotherapy, 2021, v. 70, n. 3, p. 763, doi. 10.1007/s00262-020-02730-5

By:

Papadopoulos, Kyriakos P.;
Lakhani, Nehal;
Falchook, Gerald S.;
Riley, Gosia;
Baeck, Johan;
Brown, Karen S.;
Gordon, Gilad;
Le, Lidya;
Wang, Judy S.

Publication type:

Article

Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus.

Published in:

American Journal of Gastroenterology (Springer Nature), 2010, v. 105, n. 5, p. 1039, doi. 10.1038/ajg.2009.629

By:

Wang, Judy S;
Varro, Andrea;
Lightdale, Charles J;
Lertkowit, Nantaporn;
Slack, Kristen N;
Fingerhood, Michael L;
Tsai, Wei Yann;
Wang, Timothy C;
Abrams, Julian A

Publication type:

Article

Erratum: Elevated Serum Gastrin Is Associated With a History of Advanced Neoplasia in Barrett's Esophagus.

Published in:

2010

By:

Wang, Judy S.;
Varro, Andrea;
Lightdale, Charles J.;
Lertkowit, Nantaporn;
Slack, Kristen N.;
Fingerhood, Michael L.;
Wei Yann Tsai;
Wang, Timothy C.;
Abrams, Julian A.

Publication type:

Erratum

Correction to: CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Published in:

2024

By:

Armstrong, Andrew J.;
Geva, Ravit;
Chung, Hyun Cheol;
Lemech, Charlotte;
Miller Jr, Wilson H.;
Hansen, Aaron R.;
Lee, Jong-Seok;
Tsai, Frank;
Solomon, Benjamin J.;
Kim, Tae Min;
Rolfo, Christian;
Giranda, Vincent;
Ren, Yixin;
Liu, Fang;
Kandala, Bhargava;
Freshwater, Tomoko;
Wang, Judy S.

Publication type:

Correction Notice

CXCR2 antagonist navarixin in combination with pembrolizumab in select advanced solid tumors: a phase 2 randomized trial.

Published in:

Investigational New Drugs, 2024, v. 42, n. 1, p. 145, doi. 10.1007/s10637-023-01410-2

By:

Armstrong, Andrew J.;
Geva, Ravit;
Chung, Hyun Cheol;
Lemech, Charlotte;
Miller Jr., Wilson H.;
Hansen, Aaron R.;
Lee, Jong-Seok;
Tsai, Frank;
Solomon, Benjamin J.;
Kim, Tae Min;
Rolfo, Christian;
Giranda, Vincent;
Ren, Yixin;
Liu, Fang;
Kandala, Bhargava;
Freshwater, Tomoko;
Wang, Judy S.

Publication type:

Article

A dose escalation/expansion study evaluating dose, safety, and efficacy of the novel tyrosine kinase inhibitor surufatinib, which inhibits VEGFR 1, 2, & 3, FGFR 1, and CSF1R, in US patients with neuroendocrine tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 421, doi. 10.1007/s10637-023-01359-2

By:

Dasari, Arvind;
Hamilton, Erika P.;
Falchook, Gerald S.;
Wang, Judy S.;
Li, Daneng;
Sung, Max W.;
Chien, Caly;
Nanda, Shivani;
Tucci, Christopher;
Hahka-Kemppinen, Marjo;
Paulson, Andrew Scott

Publication type:

Article

Results of an open-label phase 1b study of the ERK inhibitor MK-8353 plus the MEK inhibitor selumetinib in patients with advanced or metastatic solid tumors.

Published in:

Investigational New Drugs, 2023, v. 41, n. 3, p. 380, doi. 10.1007/s10637-022-01326-3

By:

Stathis, Anastasios;
Tolcher, Anthony W.;
Wang, Judy S.;
Renouf, Daniel J.;
Chen, Lin-Chi;
Suttner, Leah H.;
Freshwater, Tomoko;
Webber, Andrea L.;
Nayak, Tapan;
Siu, Lillian L.

Publication type:

Article

A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.

Published in:

Investigational New Drugs, 2021, v. 39, n. 5, p. 1284, doi. 10.1007/s10637-021-01088-4

By:

Falchook, Gerald S.;
Peeters, Marc;
Rottey, Sylvie;
Dirix, Luc Y.;
Obermannova, Radka;
Cohen, Jonathan E.;
Perets, Ruth;
Frommer, Ronnie Shapira;
Bauer, Todd M.;
Wang, Judy S.;
Carvajal, Richard D.;
Sabari, Joshua;
Chapman, Sonya;
Zhang, Wei;
Calderon, Boris;
Peterson, Daniel A.

Publication type:

Article

Open-Label, Multicenter, Phase I Study to Assess Safety and Tolerability of Adavosertib Plus Durvalumab in Patients with Advanced Solid Tumors: Adavosertib Plus Durvalumab for Solid Tumors: A Phase I Study: M.R. Patel et al.

Published in:

Targeted Oncology, 2025, v. 20, n. 1, p. 127, doi. 10.1007/s11523-024-01110-8

By:

Patel, Manish R.;
Falchook, Gerald S.;
Wang, Judy S.;
Imedio, Esteban Rodrigo;
Kumar, Sanjeev;
Miah, Kowser;
Mugundu, Ganesh M.;
Jones, Suzanne F.;
Spigel, David R.;
Hamilton, Erika P.

Publication type:

Article

Adavosertib in Combination with Olaparib in Patients with Refractory Solid Tumors: An Open-Label, Dose-Finding, and Dose-Expansion Phase Ib Trial.

Published in:

Targeted Oncology, 2024, v. 19, n. 6, p. 879, doi. 10.1007/s11523-024-01102-8

By:

Hamilton, Erika P.;
Falchook, Gerald S.;
Wang, Judy S.;
Fu, Siqing;
Oza, Amit M.;
Imedio, Esteban Rodrigo;
Kumar, Sanjeev;
Ottesen, Lone;
Mugundu, Ganesh M.;
de Bruin, Elza C.;
O'Connor, Mark J.;
Jones, Suzanne F.;
Spigel, David R.;
Li, Bob T.

Publication type:

Article

A Phase 1b Trial of Prexasertib in Combination with Standard-of-Care Agents in Advanced or Metastatic Cancer.

Published in:

Targeted Oncology, 2021, v. 16, n. 5, p. 569, doi. 10.1007/s11523-021-00835-0

By:

Moore, Kathleen N.;
Hong, David S.;
Patel, Manish R.;
Pant, Shubham;
Ulahannan, Susanna V.;
Jones, Suzanne;
Meric-Bernstam, Funda;
Wang, Judy S.;
Aljumaily, Raid;
Hamilton, Erika P.;
Wittchen, Erika S.;
Wang, Xuejing;
Lin, Aimee Bence;
Bendell, Johanna C.

Publication type:

Article